Spliceosome mutations: 1 plus 1 does not always equal 2 by Pellagatti, A, Boultwood, J

SF3B1 mutant myelodysplastic syndrome: Recent advances by Pellagatti, A, Boultwood, J

Reduced translation of GATA1 in Diamond-Blackfan anemia. by Boultwood, J, Pellagatti, A

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. by Pellagatti, A, Boultwood, J

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome. by Boultwood, J, Pellagatti, A, Wainscoat, J

5q- syndrome. by Boultwood, J, Pellagatti, A, Wainscoat, J

Gene expression profiling in the myelodysplastic syndromes. by Pellagatti, A, Fidler, C, Wainscoat, J, Boultwood, J

Advances in the 5q- syndrome. by Boultwood, J, Pellagatti, A, McKenzie, A, Wainscoat, J

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. by Boultwood, J, Dolatshad, H, Varanasi, S, Yip, B, Pellagatti, A

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. by Boultwood, J, Yip, B, Vuppusetty, C, Pellagatti, A, Wainscoat, J

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes by Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches by Armstrong, R, Steeples, V, Singh, S, Sanchi, A, Boultwood, J, Pellagatti, A

Neutrophil gene expression in chronic myeloproliferative disorders. by Eagleton, H, Pellagatti, A, Campbell, L, Littlewood, T, Wainscoat, J, Boultwood, J

The effects of severe hypoxia on glycolytic flux and enzyme activity in a model of solid tumors by Smith, H, Board, M, Pellagatti, A, Turley, H, Boultwood, J, Callaghan, R

Application of induced pluripotent stem cell technology for the investigation of hematological disorders by Dolatshad, H, Tatwavedi, D, Ahmed, D, Tegethoff, J, Boultwood, J, Pellagatti, A

Gene expression profiling in polycythemia vera using cDNA microarray technology. by Pellagatti, A, Vetrie, D, Langford, C, Gama, S, Eagleton, H, Wainscoat, J, Boultwood, J

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation by Liberante, F, Pellagatti, A, Boncheva, V, Bowen, D, Mills, K, Boultwood, J, Guinn, B

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. by Liberante, F, Pellagatti, A, Boncheva, V, Bowen, D, Mills, K, Boultwood, J, Guinn, B

Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders by Zhang, J, Pellagatti, A, Campbell, L, Eagleton, H, Gal, S, Fidler, C, Boultwood, J, Wainscoat, J

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF by Nikpour, M, Pellagatti, A, Jadersten, M, Forsblom, A, Wainscoat, J, Boultwood, J, Hellstroem-Lindberg, E